Review of Publication. As soon as is practicable prior to the oral public disclosure, and prior to the submission to any outside person for publication of a manuscript describing the scientific data resulting from any stage of the Early Stage Development Program or Later Stage Clinical Development, Introgen or RPRP, as the case may be, shall disclose to the Development Committee the disclosure or manuscript to be made or submitted, and shall allow the Development Committee at least thirty (30) days to determine whether such disclosure or manuscript contains subject matter for which patent protection should be sought prior to publication or which the other believes should be modified to avoid necessary regulatory or commercial difficulties. With respect to publications by investigators or other third parties, such publications shall be subject to review by the Development Committee under this Section 2.5 to the extent that Introgen or RPRP (as the case may be) has the right to do so.
Review of Publication. As soon as is practicable, and prior to any disclosure (in whatever form or format, whether in writing or orally), or submission to any Third Party for publication of a manuscript, describing or containing scientific data resulting from any work accomplished as part of the Development Program (a “Publication”), BN and its Affiliates or Crucell and its Affiliates, as the case may be, shall disclose to each Party the intended Publication, and shall allow each Party at least [***] to determine whether such Publication contains subject matter for which patent protection should be sought prior to publication or which the other believes should be modified to avoid necessary regulatory or commercial difficulties or disclosure of that Party’s confidential information. With respect to publications by investigators or other Third Parties, such publications shall be subject to review by the Operations Committee under this Section.
Review of Publication. As soon as is practicable prior to the oral --------------------- public disclosure, and prior to the submission to any outside person for public dissemination of a manuscript describing the scientific data with respect to Standard Beads or Magnetic Beads, in each case to the extent the contents of the oral disclosure or manuscript have not been previously disclosed pursuant to this Section 10.3 before such proposed disclosure, BIO-RAD shall disclose to LUMINEX the disclosure or manuscript to be made or submitted, and shall allow LUMINEX at least thirty (30) days to determine whether such disclosure or manuscript contains subject matter for which patent protection should be sought prior to publication or which LUMINEX reasonably believes should be modified to avoid (i) disclosure of information of a confidential or proprietary nature, or (ii) regulatory or other similar problems.
Review of Publication. As soon as is practicable, and in any event prior to any disclosure (in whatever form or format, whether in writing or orally) or submission to any Third Party for publication of a document describing or containing scientific data resulting from any work accomplished as part of the Development Program (a “Publication”), BN and its Affiliates or Xxxxxxx and its Affiliates, as the case may be, shall disclose to each Party the intended Publication, and shall allow each Party at least thirty (30) days to determine whether such Publication contains subject matter for which patent protection should be sought prior to publication or which the other believes should be modified to avoid necessary regulatory or commercial difficulties or disclosure of that Party’s Confidential Information. Xxxxxxx shall be free to publish without such review any marketing or commercial materials related to Licensed Components or Licensed Products, as well as any scientific data generated by or on behalf of Xxxxxxx in connection with Commercialization, provided that any materials containing previously unpublished data from Clinical Studies including an MVA-BN Vector is subject to the prior review of BN in accordance with this Section.
Review of Publication. For scientific data resulting from the Research Program or the Development Program which the Steering Committee has approved in principle should be published, the party who produced such results shall have the right to publish the same in accordance with this Section 5.2. The Steering Committee shall approve (with or without conditions) or disapprove any such publication within thirty (30) days of a request to do so, taking into consideration the commercial and competitive consequences of such publication; and if the Steering Committee fails to so approve or disapprove within such period (other than due to an action or inaction of the party proposing such publication), the publication shall be deemed approved.
Review of Publication. As soon as is practicable prior to the oral public disclosure, and prior to the submission to any outside person for publication of a manuscript describing the scientific data resulting from any work accomplished as part of the DEVELOPMENT PROGRAM, AvP and its AFFILIATES or CRUCELL and its AFFILIATES, as the case may be, shall disclose to the STEERING COMMITTEE the disclosure or manuscript to be made or submitted, and shall allow the STEERING COMMITTEE at least thirty (30) days to determine whether such disclosure or manuscript contains subject matter for which patent protection should be sought prior to publication or which the other believes should be modified to avoid necessary regulatory or commercial difficulties or disclosure of that Party's confidential information. With respect to publications by investigators or other third parties, such publications shall be subject to review by the STEERING COMMITTEE under this Section to the extent that AvP or CRUCELL (as the case may be) has the right to do so.
Review of Publication. As soon as is practicable prior to the oral public disclosure, and prior to the submission to any third party for public dissemination of information describing the scientific data with respect to Products generated in any stage of the pre-clinical or clinical trials in each case to the extent the contents of the oral disclosure or manuscript have not been previously disclosed pursuant to this Section 11(d) before such proposed disclosure, Visionex shall disclose to ACS the information to be disclosed, and shall allow ACS at least thirty (30) days to determine whether such disclosure contains subject matter for which patent protection should be sought prior to publication or which ACS reasonably believes should be modified to avoid (i) disclosure of information of a confidential or proprietary nature, or (ii) regulatory or other similar problems.
